DocWire News spoke with Douglas Sborov, MD, Director of the Multiple Myeloma Program, Huntsman Cancer Institute at the University of Utah, about recent initiatives to expand eligibility to multiple myeloma (MM) clinical trials, and the challenges this may present.

This is the final of a two-part discussion with Dr. Sborov. Watch part one, where he discusses MM care during the pandemic.